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Abstract
OBJECTIVE: To evaluate the curative effect of exter-
nal application of the Chinese drug, Sanjierupi Gao,
on mastalgia caused by mammary gland hyperpla-
sia.
METHODS: This randomized, double-blinded, and
placebo controlled study enrolled 260 patients
with mammary gland hyperplasia from five hospi-
tals. Patients were randomly and equally divided in-
to a Sanjierupi Gao treatment group and a placebo
control group. An adhesive plaster was applied to
the most painful area on either breast for 7 h a day.
Treatment lasted for two menstrual cycles without
application during menstruation. Mastalgia was
used as the main index of curative effect. The
change before and after treatment in days of mas-
talgia, the time to alleviate pain, pain extent, and
severe pain scores were observed.
RESULTS: Compared to the control group, the treat-
ment group had significantly fewer days of mastal-
gia (P<0.01), a significantly lower severe pain score
(P<0.01), and significantly less subjective pain and
tenderness (P<0.05 and P<0.01, respectively). Three
days before the follow-up visit, the pain score in
the treatment group was significantly lower than
that in the control group (P<0.05). A non-paramet-
ric test was used to compare the time to alleviate
mastalgia between the two groups and found no
statistical difference (Z=−0.313, P=0.754).
CONCLUSION: Application of Sanjierupi Gao can
decrease mastalgia duration in patients with mam-
mary gland hyperplasia during menstruation and
alleviate the extent of mastalgia. The time to allevi-
ate pain is psychologically influenced.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Hyperplasia of mammary glands is characterized by cy-
clic mastalgia,1,2 which often appears or is aggravated
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several days before menstruation and often fluctuates
with emotional changes.3,4
The treatment of mammary gland hyperplasia aims to
alleviate discomfort or pain. Because the mammary
glands are close to the body surface, externally applied
drugs can be absorbed by the skin and directly alleviate
more effectively than orally administered drugs.5 How-
ever, there is no standardized research into the curative
effect of external treatment on mastalgia caused by
mammary gland hyperplasia. Additionally, placebos
can produce analgesic effects because pain has an ex-
tremely strong emotional influence.6,7 Therefore, we
performed a randomized, double-blind, and placebo
controlled study to clinically evaluate the curative ef-
fect of external application of the Chinese drug Sanji-
erupi Gao on mastalgia caused by mammary gland hy-
perplasia.
METHODS
General data
Two hundred and sixty outpatients with mammary
gland hyperplasia from The Third Hospital Affiliated
to Beijing University of Traditional Chinese Medicine
(TCM), Sino-Japanese Friendship Hospital, Dongfang
Hospital under Beijing University of TCM, The First
Hospital Affiliated to Tianjin University of TCM, and
The Hubei Provincial Hospital of TCM from May
2010 to October 2011 (52 patients from each center)
were randomly and equally divided into the treatment
and placebo group using computer generated random
number sequence. Stratification block randomization
methods were used to ensure the balance of partici-
pants among centers and between groups. Sealed
opaque envelops were used to conceal the allocation se-
quence.
Standard of diagnosis
The standard of diagnosis was created in reference to
the principles for instructing clinical research into the
treatment of hyperplasia of mammary glands with new
Chinese drugs8 and TCM Surgery (the sixth edition).9
Mammary gland hyperplasia can be clinically diag-
nosed by mastalgia, breast tumors, disturbed or uneven
and stronger echo of breast tissues, or cystic dilatation
of mammary ducts in color ultrasonography.
Standards of inclusion and exclusion
Standards of inclusion: female patients conforming to
the standard for diagnosing hyperplasia of mammary
glands were 18-50 years old with a regular menstrual
cycle (28±7) days and menstruation. Patients had a vi-
sual analogue scale score (VAS)>3, moderate pain, cy-
clic mastalgia before menstruation, and an illness
course ≥3 months. Patients had not accepted treatment
for mammary hyperplasia within one month and had
not used hormones within six months. Patients did not
have skin lesions or dermatosis and voluntarily accept-
ed the test and gave informed consent.
Standard of exclusion: patients conformed to the stan-
dard for diagnosing mammary gland hyperplasia but
had no cyclic mastalgia. Patients had breast cancer, in-
flammation or endocrine diseases. Patients had irregu-
lar menstrual cycles or menstruation. Patients had se-
vere primary diseases of the cerebrocardiovascular sys-
tem, liver, kidney, hematopoietic system, or mental dis-
ease. Female patients were pregnant, lactating, in meno-
pause, or preparing to be pregnant. Patients had aller-
gic constitution or were sensitive to the drugs used. Pa-
tients were taking part in other clinical tests.
This experiment was approved by the ethics committee
of the Third Hospital affiliated to Beijing University of
TCM with the approval number 2010007. All patients
gave informed consent. This experiment was registered
at China Center for registering clinical experiments
with the registration number ChiCTR-TRC-
12002920.
Therapy
In the treatment group, an adhesive plaster of Sanjieru-
pi Gao was applied to the most painful location on ei-
ther breast for 7 h a day.
In the control group, a placebo was applied to the most
painful place on either breast for 7 h a day.
Sanjierupi Gao and the placebo were produced by
Hexiang Pharmaceutical Limited Company (batch
number: Z20040073, Heilongjiang, China). The place-
bo match the Sanjierupi Gao in appearance, color,
smell, etc. The two groups were treated for two men-
strual cycles without treatment during menstruation.
Patients made a follow-up visit for two menstrual cy-
cles to evaluate patients after withdrawal.
Index and method of observation
The patients gave mastalgia scores on the VAS daily.
The time calculated by days when VAS score decreased
by two was defined as the first length of time to allevi-
ate pain. The days of mastalgia in every menstrual cy-
cle were calculated according to the record of pain. The
severe mastalgia score was found according to the pa-
tient's record of pain. According to the extent of mas-
talgia and tenderness in the luteal phase, the researcher
divided pain into no pain, mild pain, moderate pain,
and severe pain and chose the corresponding pain ex-
tent in case report form . According to the record of
pain in the two groups, the average pain value was tak-
en from the scores of pain within 3 days before the fol-
low-up visit to reflect the extent of mastalgia during
the luteal phase.
Statistical analysis
SAS 6.0 (SAS Insititute, Cary, NC, USA) was used to
generate random number sequence. SPSS 17.0 (SPSS
Inc., Chicago, IL, USA) software was used to do statis-
tical analysis. Completed, rejected, and dropout pa-
tients were counted in the five centers. Homogeneous
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analysis of baseline values and demography in the two
groups was carried out. Measured value (baseline) and
the difference among patients at different centers were
processed as covariance to deduct the influence of the
main index to enhance the efficiency of statistical analy-
sis. To inspect the comparability between the two
groups, effective analysis was used to observe indexes of
pain. The full analysis set (FAS) and per protocol set
(PPS) was reported. P≤0.05 was considered significant
difference. This research is reported according to the
detailed list in the statement of Consort 2010 report.10
RESULTS
Basic patient information and inclusion procedure
diagram
Among the 260 patients in the FAS were 130 patients
in the treatment group and 130 in the control group.
Because of seven dropouts, among the 253 patients in
the PPS were 123 patients in the treatment group and
130 in the control group.
The baseline data including age, height, body weight,
pulse and respiratory rate, educational level, marital
state, reproductive history, breast-feeding history, and
familial history were comparable between the two
groups (P>0.05).
Comparison of days of mastalgia during menstrual
cycles between two groups
For the PPS analysis, the test of normality showed that
the data of mastalgia time at various stages in both
groups were not normally distributed (P<0.01). A
non-parametric test used to compare the difference in
mastalgia time at various stages between the two
groups showed that the mastalgia time before treat-
ment could be compared (P>0.05) between the two
groups. After two courses of treatment, the mastalgia
time in the treatment group was significantly shorter
than that in the control group (P<0.01). The results of
the FAS analysis were the same as that of the PPS analy-
sis (Table 1).
Comparison of scores of severe mastalgia during
menstrual cycle between the two groups
For the PPS analysis, the test of normality showed that
the data at various stages in both groups were not nor-
mally distributed (P<0.01). A non-parametric test used
to compare the scores of severe mastalgia at various
stages between the two groups showed that the scores
of severe mastalgia before treatment could be com-
pared between the two groups (P>0.05). After one
course of treatment, there was no obvious difference in
the severe mastalgia scores between the two groups
(P>0.05). After two courses of treatment, the severe
mastalgia score in the treatment group was significant-
ly lower than that in the control group (P<0.01). The
results of the FAS analysis were the same as that of the
PPS analysis (Table 2).
Comparison of time to alleviate mastalgia after
treatment between the two groups
The time at which the VAS mastalgia score decreased
by two was defined as the first time to taking effect.
The time to take analgesic effect after treatment was
(4±7) days in the treatment group and (4±6) days in
the control group. A test of normality showed that the
data in both groups were not normally distributed (P<
0.01). A non-parametric test used to compare the time
to take effect between the two groups showed Z=−
0.313 andP=0.754, so therewas no statistical difference.
Comparison of mastalgia extent between the two
groups
A test of normality showed that the data of symptoms at
Treatment course
Before treatment
After one course of treatment
After 2 courses of treatment
PPS
Treatment group
8±4
13±9
11±9
Control group
8±4
13±8
13±8
P
0.556
0.418
0.008
FAS
Treatment group
8±4
13±8
11±9
Control group
8±4
13±8
13±8
P
0.570
0.358
0.011
Table 1 Comparison of days suffering frommastalgia between the Sanjierupi Gao and placebo group
Notes: Sanjierupi Gao was applied to the treatment group for 7 h a day. The control group received a placebo treatment. PPS: per protocol
analysis; FAS: full analysis set.
Treatment course
Before treatment
After one course of treatment
After 2 courses of treatment
PPS
Treatment group
6.0±1.2
5.1±1.7
3.4±2.1
Control group
5.8±1.4
5.5±1.6
4.6±2.0
P
0.183
0.054
<0.001
FAS
Treatment group
6.0±1.2
5.1±1.7
3.5±2.1
Control group
5.8±1.4
5.5±1.6
4.6±2.0
P
0.189
0.057
<0.001
Table 2 Comparison of scores of severe mastalgia between the two groups
Notes: Sanjierupi Gao was applied to the treatment group for 7 h a day. The control group received a placebo treatment. PPS: per protocol
analysis; FAS: full analysis set.
605
JTCM |www. journaltcm. com
Fan YY et al. / Clinical Study
October 15, 2013 |Volume 33 | Issue 5 |
various stages were not normally distributed (P<0.001).
A non-parametric test used to compare the accumulat-
ed scores of symptoms at various stages showed that
breast-related symptoms at baseline could be compared
(P>0.05). The extent of mastalgia and tenderness in
the treatment group was not as great as that in the con-
trol group, with statistical difference (P<0.05) after one
course of treatment and (P<0.01) after two courses of
treatment (Table 3).
Comparison of mastalgia scores during the luteal
phase between the two groups 3 days before the fol-
low-up visit
For the PPS analysis, a test of normality showed that
the data at various stages in both groups were not nor-
mally distributed (P<0.01). A non-parametric test
showed that the mastalgia scores in the two groups
could be compared 3 days before treatment (P>0.05).
The mastalgia score in the treatment group was signifi-
cantly lower than that in the control group 3 days after
one course of treatment and 3 days after two courses of
treatment (P<0.05). The results of the FAS analysis
were the same as that of the PPS analysis (Table 4).
DISCUSSION
In recent years, research on the external treatment of
mammary gland hyperplasia with Chinese medicine
has shown promise.5,11-15 To popularly use external Chi-
nese drug treatment for mammary gland hyperplasia
with, the curative effect and safety must be evaluated
through clinically standardized research with large sam-
ple sizes at many centers. Sanjierupi Gao, mainly com-
posed of Ezhu (Rhizoma Curcumae Phaeocaulis), Jiang-
huang (Rhizoma Curcumae Longae), Jixingzi (Semen Im-
patientis), Tiankuizi (Radix Semiaquilegiae), and Baizhi
(Radix Angelicae Formosanae), can promote circulation
of Qi and blood, remove masses and eliminate swell-
ing. In this study, mastalgia was used as a main index
of curative effect. The statistical analysis of mastalgia
scores showed that after treatment for two menstrual
cycles, there were significantly fewer days of mastalgia
during the menstrual cycle in the treatment group than
in the control group (P<0.01). Therefore, externally ap-
plied drugs could shorten the time of mastalgia.
Statistical analysis showed that after treatment for two
menstrual cycles, the severe mastalgia score in the treat-
ment group was significantly lower than that in the
control group (P<0.01). Therefore, externally applied
drugs could lessen the extent of mastalgia. Moreover,
statistical analysis of mastalgia scores in the two groups
during the luteal phase 3 days before the follow-up vis-
it showed that after the first treatment course and after
the second treatment course, the mastalgia score in the
treatment group was significantly lower than that in
the control group (P<0.05). Therefore, externally ap-
plied drugs could lessen mastalgia, especially during
the luteal phase.
We also observed the time to take analgesic effect. Ac-
cording to the recorded mastalgia scores, the time cal-
culated in days when the VAS score decreased by two
was defined as the first time to take effect. To ex-
clude the influence of menstruation on mastalgia, pa-
tients whose pain score during menstruation de-
creased by two were rejected. A non-parametric test
used to compare the time to take effect on alleviat-
ing mastalgia between the two groups showed Z=
− 0.313 and P=0.754 without statistical difference.
Therefore, the time to take analgesic effect is psycho-
logically influenced. Moreover, the unreasonable influ-
ence of the plan for evaluating the time to take ef-
fect on mastalgia pain cannot be excluded. Therefore,
the method to evaluate the time to take analgesic ef-
fect must be further investigated.
Item
Extent of mastalgia
Extent of breast tenderness
Group
Treatment group
Control group
Treatment group
Control group
Baseline
6.0±1.3
5.9±1.4
2.2±0.6
2.1±0.7
1 course of treatment
4.0±2.1
4.6±2.2a
1.4±0.8
1.7±0.8b
2 courses of treatment
2.8±2.1
4.3±2.2b
1.0±0.7
1.6±0.9b
Table 3 Comparison of mastalgia extent between the two groups
Notes: Sanjierupi Gao was applied to the treatment group for 7 h a day. The control group received a placebo treatment. aP<0.05 and
bP<0.01, as compared with the datum in the treatment group.
Treatment course
Before treatment
1 course of treatment
2 courses of treatment
PPS
Treatment group
3.87±2.09
2.36±2.00
2.17±2.01
Control group
3.83±1.99
2.99±2.15
2.94±2.37
P
0.628
0.015
0.017
FAS
Treatment group
3.92±2.11
2.37±1.99
2.22±2.03
Control group
3.83±1.99
3.01±2.14
2.97±2.37
P
0.534
0.013
0.015
Table 4 Comparison of mastalgia scores between the two groups 3 days before the follow-up visit
Notes: Sanjierupi Gao was applied to the treatment group for 7 h a day. The control group received a placebo treatment. Two patients
dropped out before treatment, two dropped out after one course of treatment and five dropped out after two courses of treatment from the
control group. Two patients dropped out from the treatment group. PPS: per protocol analysis; FAS: full analysis set.
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